Positron-Emission Tomography
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
ImaginAbCA - Inglewood
2 programs1
1
⁸⁹Zr-Df-IAB22M2CPhase 21 trial
⁸⁹Zr-Df-IAB22M2C InfusionPhase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
ImaginAb⁸⁹Zr-Df-IAB22M2C
ImaginAb⁸⁹Zr-Df-IAB22M2C Infusion
Clinical Trials (2)
Total enrollment: 67 patients across 2 trials
⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors
Start: Dec 2018Est. completion: Jul 202252 patients
Phase 2Completed
⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma
Start: Jun 2017Est. completion: Aug 201815 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.